In recent years, the "tide" of dietary health has blown to the younger generation, and at the same time, young people have also given new vitality to the dietary health market. As a leading brand in the dietary supplement industry, By-Health firmly grasps the market changes, keeps up with the changes of the times, and continues to move forward in the direction of strong scientific and technological transformation under the scientific nutrition strategy led by the founder Liang Yunchao. On the evening of February 20, the 2023 annual performance report of Tomson By-Health was released, and Tomson's revenue steadily increased to attract attention.
According to the Blue Book of China's Nutrition and Health Food, as of 2022, the scale of China's nutrition and health food industry has reached RMB588.5 billion, and the industry is expected to exceed RMB800 billion by 2027. In view of the broad industry prospects, Liang Yunchao, the founder of Tomson By-Health, issued a letter to shareholders at the beginning of 2022 "Use another eight years to build a strong technology-based enterprise", and put forward a strategic vision for the future direction of Tomson By-Health, that is, to use eight years to initially complete a strong technology-based enterprise, focus the company's resources on "heavy function" products, and drive product power with science and technology.
Under the strategy of "scientific nutrition", By-Health continues to promote the transformation of strong technology enterprises and the strategy of strengthening brands, laying out multi-brand, large single products, all categories, all channels, and single focus, focusing on the market goal of increasing the designated purchase rate and omni-channel market share, and actively meeting the challenges of the new cycle.
Focusing on "new raw materials, new functions and new technologies", and using science and technology to drive product strength, Tomson By-Health continues to tap the incremental market. A number of major R&D achievements have been announced. In terms of research and development of patented raw materials and formulas, as of the end of June 2023, By-Health has obtained 370 patents, including 103 invention patents for raw materials and formulas, and 139 health food approval certificates.
Among them, By-Health and scientific research institutions jointly discovered the substance PCC1, which "accurately removes senescent cells", which has become a "new milestone in the fight against aging" in the field, and this achievement was published in the international authoritative journal "Nature". In addition, the scientific research results of innovative raw materials for collagen peptides containing GAGS, an important ingredient in the dermis, have also become word-of-mouth products after landing on the product.
Judging from the 2023 Tomson Beijian performance report, the company's operating income in 2023 will be about 940.7 billion yuan, an increase of 19 percent year-on-year66%；The net profit attributable to shareholders of the listed company was about 174.6 billion yuan, an increase of 26% year-on-year. The strong science and technology transformation strategy under the guidance of the "scientific nutrition" strategy has achieved remarkable results, and the second year of the new VDS cycle has begun.